- Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Expires: February 28, 2011 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

CLARK PAUL N

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/30/2009

3. Issuer Name and Ticker or Trading Symbol

Talecris Biotherapeutics Holdings Corp. [TLCR]

(Last) (First) (Middle)

C/O TALECRIS BIOTHERAPEUTICS HOLDINGS, P.O. BOX 110526 4101 RESEARCH COMMONS

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

RESEARCH TRIANGLE PARK, NC 27709

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9696 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options (right to buy)	4/1/2008	9/11/2017	Common Stock	8576	$11.00	D
Options (right to buy)	4/1/2009	4/21/2018	Common Stock	12616	$9.88	D
Options (right to buy)	4/1/2010 ⁽²⁾	3/27/2019	Common Stock	7848 ⁽²⁾	$16.63	D

Explanation of Responses:
( 1)	The number of shares reflected in this row includes 3,616 shares that have not yet vested of the Issuer's common stock that were granted to the Reporting Person on March 27, 2009. Such non-vested shares will vest on April 1, 2010, subject to the Reporting Person's continuous service with the Issuer through that date, as detailed in a restricted stock award agreement by and between the Issuer and the Reporting Person, dated as of March 27, 2009.
( 2)	The securities being reported in this row are options to purchase the Issuer's common stock that were granted by the Issuer to the Reporting Person on March 27, 2009. These options will vest and become exercisable on April 1, 2010, subject to the Reporting Person remaining a Key Person (as defined in the Issuer's 2005 Stock Option and Incentive Plan) with the Issuer through that date, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of March 27, 2009.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CLARK PAUL N C/O TALECRIS BIOTHERAPEUTICS HOLDINGS P.O. BOX 110526 4101 RESEARCH COMMONS RESEARCH TRIANGLE PARK, NC 27709	X

Signatures
/s/ John F. Gaither, Jr., attorney in fact		9/30/2009
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.